Hospital
Camden Clark Memorial Hospital Corporation
Camden Clark Memorial Hospital Corporation was paid $56.26M by Medicaid between Jan 2018 and Dec 2024, across 481 billing codes. Its largest line is 99285, emergency room visit (most serious) — 11% of everything it billed.
33Billing provider infoCAMDEN CLARK MEMORIAL HOSPITAL CORPORATION
PARKERSBURG, WV 26101
PARKERSBURG, WV 26101
33aNPI1699704254assigned 07/03/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$56.26M
24GClaims1,374,029
24DCodes billed481
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in West Virginia
Rank by total paid#4 of 26
Median peer was paid$18.33M
This provider vs. median3.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 207,177 | $14.52M | |
| 2019 | 142,473 | $9.86M | |
| 2020 | 240,830 | $15.83M | |
| 2021 | 225,818 | $5.01M | |
| 2022 | 139,606 | $2.78M | |
| 2023 | 221,983 | $4.19M | |
| 2024incomplete | 196,142 | $4.07M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 17,997 | 15,243 | $6.40M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.3% | 31,077 | 26,849 | $5.24M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.5% | 29,766 | 26,377 | $3.12M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.6% | 7,389 | 6,520 | $2.00M |
| 80053 | Comprehensive metabolic panel | 2.6% | 83,523 | 67,418 | $1.46M |
| 41899 | Unlisted procedure, dentoalveolar structures | 2.5% | 1,039 | 819 | $1.40M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.1% | 83,208 | 63,575 | $1.19M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.8% | 4,472 | 4,138 | $996K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.5% | 2,377 | 2,143 | $854K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 8,922 | 7,902 | $852K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 14,440 | 9,601 | $788K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 19,605 | 14,277 | $715K |
469 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.2% | 4,812 | $697K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 18,483 | $674K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 3,284 | $639K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 38,298 | $622K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.0% | 8,237 | $574K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 11,081 | $532K |
| G0378 | Hospital observation service, per hour | <1% | 11,422 | $521K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,955 | $519K |
| 84484 | <1% | 23,967 | $480K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 19,916 | $472K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 5,582 | $463K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 14,869 | $449K |
| 0099U | <1% | 1,033 | $435K | |
| 96376 | <1% | 6,530 | $432K | |
| 81001 | <1% | 29,017 | $427K | |
| 85027 | <1% | 24,713 | $419K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 18,069 | $419K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,322 | $415K |
| 81025 | <1% | 13,437 | $404K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 4,123 | $391K |
| 71045 | Radiologic examination, chest; single view | <1% | 19,213 | $385K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 2,405 | $375K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 13,503 | $365K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 10,475 | $357K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,193 | $334K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,930 | $332K |
| 93017 | <1% | 2,981 | $330K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 19,405 | $326K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 7,117 | $318K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,533 | $305K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,159 | $300K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 3,321 | $300K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,625 | $293K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,608 | $287K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 747 | $281K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 18,448 | $274K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 7,541 | $269K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,710 | $269K |
| 36415 | Collection of venous blood by venipuncture | <1% | 50,041 | $266K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 14,449 | $264K |
| 83735 | <1% | 18,135 | $259K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 6,150 | $255K |
| 80061 | Lipid panel | <1% | 13,036 | $251K |
| 83690 | <1% | 13,371 | $251K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,108 | $243K |
| 64493 | <1% | 180 | $241K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,796 | $239K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 16,697 | $236K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,329 | $235K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,798 | $232K |
| 85610 | <1% | 22,145 | $230K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 2,954 | $230K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,678 | $222K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,561 | $202K |
| 85730 | <1% | 18,326 | $201K | |
| 81003 | <1% | 15,826 | $188K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 522 | $171K |
| 74178 | <1% | 423 | $167K | |
| 87522 | Neg quan hep c or qual rna | <1% | 2,418 | $163K |
| 82150 | <1% | 3,308 | $162K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 10,217 | $162K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 5,048 | $158K |
| 83880 | <1% | 4,665 | $155K | |
| 93880 | <1% | 2,536 | $153K | |
| 87040 | <1% | 7,416 | $152K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,133 | $150K |
| 74018 | <1% | 4,479 | $142K | |
| 71250 | <1% | 1,537 | $141K | |
| 80305 | <1% | 3,731 | $136K | |
| 87631 | <1% | 818 | $134K | |
| 96367 | <1% | 3,484 | $133K | |
| 87186 | <1% | 8,158 | $131K | |
| 72110 | <1% | 2,717 | $130K | |
| 83605 | <1% | 7,795 | $129K | |
| 80074 | <1% | 2,419 | $129K | |
| 86850 | <1% | 5,835 | $125K | |
| 88142 | <1% | 4,078 | $125K | |
| 84439 | <1% | 5,820 | $125K | |
| 83721 | <1% | 7,009 | $123K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 10,302 | $123K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 279 | $122K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,385 | $121K |
| 84702 | <1% | 4,259 | $121K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,196 | $120K |
| 85007 | <1% | 4,504 | $115K | |
| 86900 | <1% | 5,604 | $110K | |
| 76536 | <1% | 1,176 | $108K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 2,959 | $108K |
| 86140 | <1% | 9,113 | $105K | |
| 87070 | <1% | 6,601 | $100K | |
| 86901 | <1% | 5,596 | $99K | |
| 93971 | <1% | 1,742 | $97K | |
| 87088 | <1% | 6,102 | $95K | |
| 76770 | <1% | 1,087 | $94K | |
| 70486 | <1% | 643 | $91K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 137 | $88K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 270 | $87K |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 836 | $84K |
| 72141 | <1% | 140 | $84K | |
| 82803 | <1% | 3,023 | $84K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,752 | $81K |
| 93970 | <1% | 888 | $81K | |
| 86803 | <1% | 3,517 | $77K | |
| 72050 | <1% | 1,216 | $76K | |
| 88304 | <1% | 762 | $74K | |
| 82607 | <1% | 3,855 | $74K | |
| 73630 | <1% | 2,778 | $73K | |
| 76642 | <1% | 1,343 | $73K | |
| 82565 | <1% | 3,538 | $70K | |
| 36600 | <1% | 2,550 | $70K | |
| 85379 | <1% | 2,885 | $69K | |
| 73030 | <1% | 2,565 | $68K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 421 | $64K |
| 74022 | <1% | 833 | $64K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 678 | $64K |
| 64494 | <1% | 118 | $64K | |
| 73130 | <1% | 1,791 | $63K | |
| 87486 | <1% | 664 | $63K | |
| 87581 | <1% | 662 | $63K | |
| 62323 | <1% | 237 | $63K | |
| 85651 | <1% | 5,493 | $62K | |
| 84145 | <1% | 2,229 | $59K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,440 | $58K |
| 84520 | <1% | 2,421 | $56K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 261 | $56K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 4,706 | $56K |
| 73610 | <1% | 1,676 | $55K | |
| 78227 | <1% | 187 | $55K | |
| 84100 | <1% | 5,256 | $55K | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 446 | $54K |
| 82728 | <1% | 3,793 | $53K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 718 | $52K |
| 87077 | <1% | 3,168 | $52K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,598 | $52K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 4,559 | $51K |
| 80051 | <1% | 1,275 | $51K | |
| 94060 | <1% | 1,928 | $51K | |
| 86756 | <1% | 655 | $50K | |
| 85018 | <1% | 2,592 | $49K | |
| 87902 | <1% | 223 | $48K | |
| 84481 | <1% | 1,410 | $48K | |
| 84460 | <1% | 1,727 | $48K | |
| 70491 | <1% | 130 | $48K | |
| 97161 | <1% | 2,013 | $47K | |
| 87276 | <1% | 1,099 | $46K | |
| 84450 | <1% | 1,607 | $46K | |
| 87275 | <1% | 1,101 | $46K | |
| 82247 | <1% | 2,555 | $45K | |
| 82248 | <1% | 5,305 | $45K | |
| 94726 | <1% | 1,787 | $45K | |
| 87340 | <1% | 2,740 | $44K | |
| 88342 | <1% | 1,032 | $44K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,867 | $43K |
| 93458 | <1% | 14 | $43K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 93 | $42K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 378 | $42K |
| 94729 | <1% | 1,993 | $41K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,189 | $39K |
| 87075 | <1% | 2,519 | $39K | |
| 84075 | <1% | 1,355 | $39K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,835 | $39K |
| 76830 | Ultrasound, transvaginal | <1% | 430 | $38K |
| 73562 | <1% | 1,105 | $38K | |
| 86592 | <1% | 3,831 | $37K | |
| 83655 | <1% | 1,663 | $37K | |
| 73564 | <1% | 970 | $37K | |
| 78226 | <1% | 189 | $36K | |
| A9578 | Injection, gadobenate dimeglumine (multihance multipack), per ml | <1% | 1,323 | $36K |
| 73110 | <1% | 878 | $36K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,304 | $36K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,279 | $35K |
| 90715 | <1% | 1,060 | $34K | |
| 87205 | <1% | 3,530 | $34K | |
| 74420 | <1% | 185 | $32K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 639 | $32K |
| 72100 | <1% | 784 | $31K | |
| 87081 | <1% | 1,560 | $31K | |
| 97165 | <1% | 1,355 | $31K | |
| 36000 | <1% | 354 | $30K | |
| 83970 | <1% | 1,037 | $30K | |
| 72131 | <1% | 212 | $29K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,745 | $29K |
| 87147 | <1% | 1,315 | $28K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,103 | $28K |
| 83540 | <1% | 3,519 | $28K | |
| 80050 | General health panel | <1% | 695 | $27K |
| 73560 | <1% | 892 | $27K | |
| 82746 | <1% | 1,473 | $27K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 1,986 | $25K |
| 82043 | <1% | 2,964 | $25K | |
| 72040 | <1% | 531 | $25K | |
| 82553 | <1% | 620 | $25K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,101 | $25K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 325 | $24K |
| 82570 | <1% | 3,347 | $24K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,627 | $24K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 306 | $24K |
| 84153 | <1% | 1,142 | $24K | |
| 86762 | <1% | 1,122 | $24K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,111 | $23K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,451 | $23K |
| 86038 | <1% | 984 | $23K | |
| 83516 | <1% | 995 | $23K | |
| 73502 | <1% | 1,101 | $22K | |
| 88720 | <1% | 3,426 | $22K | |
| 77065 | Tomosynthesis, mammo | <1% | 384 | $22K |
| 84403 | <1% | 506 | $22K | |
| 97602 | <1% | 350 | $21K | |
| 84436 | <1% | 466 | $21K | |
| 59025 | Fetal non-stress test | <1% | 266 | $21K |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 84 | $20K |
| 72072 | <1% | 395 | $19K | |
| 86003 | <1% | 59 | $19K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 415 | $18K |
| 81596 | <1% | 247 | $18K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 1,482 | $18K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 856 | $17K |
| 86480 | <1% | 213 | $17K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 340 | $17K |
| 93296 | <1% | 1,472 | $16K | |
| 86677 | <1% | 482 | $16K | |
| 12001 | <1% | 234 | $16K | |
| 84146 | <1% | 442 | $16K | |
| 74246 | <1% | 281 | $16K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,517 | $15K |
| 86703 | <1% | 480 | $15K | |
| 84112 | <1% | 174 | $14K | |
| 82550 | <1% | 1,359 | $14K | |
| 73080 | <1% | 455 | $14K | |
| 73590 | <1% | 399 | $13K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 46 | $13K |
| 84132 | <1% | 224 | $13K | |
| J2805 | Injection, sincalide, 5 micrograms | <1% | 184 | $13K |
| 73221 | <1% | 27 | $13K | |
| 86706 | <1% | 680 | $13K | |
| 94618 | <1% | 410 | $13K | |
| 84550 | <1% | 1,938 | $12K | |
| 88185 | <1% | 142 | $12K | |
| 82950 | <1% | 971 | $12K | |
| 84402 | <1% | 191 | $12K | |
| 70498 | <1% | 413 | $12K | |
| 96523 | <1% | 407 | $12K | |
| 70496 | <1% | 287 | $11K | |
| 84466 | <1% | 2,066 | $11K | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 345 | $11K |
| 86431 | <1% | 714 | $11K | |
| 82947 | <1% | 951 | $11K | |
| 86200 | <1% | 392 | $10K | |
| 82962 | <1% | 7,546 | $10K | |
| 80076 | <1% | 659 | $10K | |
| 96415 | <1% | 353 | $10K | |
| 83525 | <1% | 432 | $9K | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 16 | $9K |
| 95819 | <1% | 45 | $9K | |
| Q9961 | High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml | <1% | 185 | $9K |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 54 | $9K |
| 84156 | <1% | 1,408 | $9K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 86 | $9K |
| 86696 | <1% | 359 | $9K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 134 | $9K |
| 97597 | <1% | 152 | $9K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 272 | $9K |
| 86376 | <1% | 163 | $8K | |
| J2704 | Injection, propofol, 10 mg | <1% | 6,348 | $8K |
| 82010 | <1% | 247 | $7K | |
| 86790 | <1% | 595 | $7K | |
| 77336 | <1% | 178 | $7K | |
| 76870 | <1% | 82 | $7K | |
| 86695 | <1% | 359 | $7K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 775 | $7K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 216 | $6K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 193 | $6K |
| 93924 | <1% | 69 | $6K | |
| 86308 | <1% | 58 | $6K | |
| 72170 | <1% | 390 | $6K | |
| 86255 | <1% | 225 | $6K | |
| 80143 | <1% | 603 | $6K | |
| 96417 | <1% | 145 | $6K | |
| 96368 | <1% | 165 | $6K | |
| 86704 | <1% | 187 | $6K | |
| 97116 | <1% | 645 | $6K | |
| 64635 | <1% | 43 | $6K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 102 | $6K |
| 93325 | <1% | 119 | $6K | |
| 78306 | <1% | 26 | $6K | |
| 73120 | <1% | 216 | $6K | |
| 88184 | <1% | 141 | $6K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 165 | $6K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 73 | $5K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 12 | $5K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 132 | $5K |
| 73090 | <1% | 181 | $5K | |
| 90686 | <1% | 356 | $5K | |
| 87324 | <1% | 191 | $5K | |
| 94664 | <1% | 113 | $5K | |
| 10060 | <1% | 81 | $5K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,303 | $5K |
| 80055 | <1% | 136 | $5K | |
| 82785 | <1% | 60 | $5K | |
| Q3014 | Telehealth originating site facility fee | <1% | 540 | $5K |
| 82310 | <1% | 391 | $5K | |
| 83615 | <1% | 848 | $5K | |
| 87427 | <1% | 193 | $5K | |
| 93923 | <1% | 159 | $4K | |
| 87045 | <1% | 230 | $4K | |
| 74230 | <1% | 89 | $4K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 235 | $4K |
| 92611 | <1% | 87 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 60 | $4K |
| 87046 | <1% | 230 | $4K | |
| 88307 | <1% | 33 | $4K | |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 25 | $4K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 617 | $4K |
| 83001 | <1% | 137 | $3K | |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | <1% | 25 | $3K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 29 | $3K |
| 93308 | <1% | 96 | $3K | |
| 73552 | <1% | 91 | $3K | |
| 76882 | <1% | 33 | $3K | |
| 86235 | <1% | 74 | $3K | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 504 | $3K |
| A9561 | Technetium tc-99m oxidronate, diagnostic, per study dose, up to 30 millicuries | <1% | 41 | $3K |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 89 | $3K |
| 82140 | <1% | 214 | $3K | |
| J1815 | Injection, insulin, per 5 units | <1% | 645 | $3K |
| 86618 | <1% | 180 | $3K | |
| 87210 | <1% | 58 | $3K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 74 | $3K |
| 71101 | <1% | 109 | $2K | |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 49 | $2K |
| 58563 | <1% | 14 | $2K | |
| 74240 | <1% | 52 | $2K | |
| 64451 | <1% | 17 | $2K | |
| 86694 | <1% | 26 | $2K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,568 | $2K |
| 82533 | <1% | 83 | $2K | |
| 86780 | <1% | 239 | $2K | |
| 94010 | <1% | 62 | $2K | |
| 80069 | <1% | 206 | $2K | |
| 86905 | <1% | 28 | $2K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 40 | $2K |
| 95806 | <1% | 53 | $2K | |
| 87209 | <1% | 49 | $2K | |
| 74019 | <1% | 131 | $2K | |
| 81513 | <1% | 16 | $2K | |
| 73522 | <1% | 32 | $2K | |
| 99495 | <1% | 186 | $2K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 543 | $2K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 30 | $1K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 136 | $1K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 130 | $1K |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 18 | $1K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 12 | $1K |
| 93242 | <1% | 95 | $1K | |
| 29125 | <1% | 15 | $1K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 49 | $1K |
| 77334 | <1% | 24 | $1K | |
| 93320 | <1% | 12 | $1K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 45 | $1K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 53 | $1K |
| 83002 | <1% | 77 | $1K | |
| 86709 | <1% | 36 | $1K | |
| 82977 | <1% | 41 | $1K | |
| 93280 | <1% | 132 | $1K | |
| 87177 | <1% | 49 | $1K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 92 | $1K |
| 77300 | <1% | 14 | $1K | |
| 93299 | <1% | 61 | $1K | |
| 83013 | <1% | 17 | $1K | |
| 73620 | <1% | 44 | $984.33 | |
| 85576 | <1% | 33 | $952.19 | |
| 80081 | <1% | 14 | $943.18 | |
| 86708 | <1% | 28 | $926.70 | |
| 85045 | <1% | 62 | $914.50 | |
| 82105 | <1% | 98 | $910.05 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 50 | $897.91 |
| 87481 | <1% | 30 | $894.16 | |
| 85046 | <1% | 245 | $847.97 | |
| 86160 | <1% | 47 | $784.15 | |
| 36569 | <1% | 16 | $784.00 | |
| 93922 | <1% | 44 | $764.01 | |
| 86364 | <1% | 103 | $746.07 | |
| J3490 | Unclassified drugs | <1% | 8,341 | $729.80 |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 17 | $715.12 |
| 36416 | <1% | 451 | $663.42 | |
| 90656 | <1% | 193 | $617.59 | |
| 12002 | <1% | 13 | $602.50 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 744 | $601.09 |
| 80164 | <1% | 45 | $583.53 | |
| 87641 | <1% | 25 | $583.51 | |
| 86800 | <1% | 15 | $560.31 | |
| 11721 | <1% | 177 | $548.67 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,831 | $530.83 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 55 | $515.75 |
| 73060 | <1% | 42 | $495.59 | |
| 82365 | <1% | 16 | $482.82 | |
| 77061 | <1% | 159 | $465.97 | |
| 77080 | <1% | 26 | $451.57 | |
| J0701 | Injection, cefepime hydrochloride (baxter), not therapeutically equivalent to maxipime, 500 mg | <1% | 67 | $441.81 |
| 88300 | <1% | 13 | $433.18 | |
| 81511 | <1% | 18 | $403.39 | |
| 72202 | <1% | 26 | $400.42 | |
| 64636 | <1% | 20 | $395.88 | |
| 84479 | <1% | 40 | $370.69 | |
| 71271 | <1% | 14 | $367.74 | |
| 93799 | <1% | 100 | $354.90 | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 14 | $331.45 |
| 82670 | <1% | 15 | $328.32 | |
| 95250 | <1% | 12 | $322.17 | |
| 96127 | <1% | 103 | $315.89 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,043 | $308.34 |
| 86147 | <1% | 14 | $302.45 | |
| 74220 | <1% | 13 | $276.45 | |
| 86705 | <1% | 30 | $267.58 | |
| 82784 | <1% | 40 | $259.73 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 309 | $254.01 |
| 93882 | <1% | 17 | $251.69 | |
| 84270 | <1% | 14 | $246.65 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 130 | $237.94 |
| 90694 | <1% | 100 | $232.50 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 156 | $205.46 |
| 76857 | <1% | 17 | $199.60 | |
| 51798 | <1% | 171 | $195.49 | |
| 93298 | <1% | 49 | $188.38 | |
| 83520 | <1% | 14 | $179.29 | |
| 82272 | <1% | 46 | $162.53 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 47 | $144.27 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 65 | $133.09 |
| 70250 | <1% | 12 | $131.46 | |
| 36592 | <1% | 14 | $129.14 | |
| 73521 | <1% | 13 | $115.97 | |
| 92610 | <1% | 16 | $102.99 | |
| 82085 | <1% | 12 | $102.24 | |
| 81002 | <1% | 60 | $95.06 | |
| 90474 | <1% | 12 | $94.90 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 628 | $92.83 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 173 | $89.08 |
| 90653 | <1% | 38 | $83.49 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 163 | $83.07 |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 14 | $82.44 |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | <1% | 271 | $78.65 |
| C1755 | Catheter, intraspinal | <1% | 35 | $76.53 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 230 | $70.88 |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 960 | $59.34 |
| A4648 | Tissue marker, implantable, any type, each | <1% | 286 | $56.71 |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 79 | $31.31 |
| A9573 | Injection, gadopiclenol, 1 ml | <1% | 189 | $25.76 |
| 93321 | <1% | 15 | $23.84 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 606 | $23.37 |
| 80349 | <1% | 200 | $15.89 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 23 | $12.99 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 42 | $12.03 |
| C1769 | Guide wire | <1% | 266 | $1.09 |
| S5553 | Insulin, long acting; 5 units | <1% | 17 | $0.60 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 78 | $0.45 |
| 90671 | 0% | 45 | $0.00 | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | 0% | 76 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 118 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 75 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 15 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 15 | $0.00 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 29 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 15 | $0.00 |
| 94070 | 0% | 14 | $0.00 | |
| 80324 | 0% | 60 | $0.00 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | 0% | 211 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 14 | $0.00 |
| J7674 | Methacholine chloride administered as inhalation solution through a nebulizer, per 1 mg | 0% | 14 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPIERSON, KYLE (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Camden Clark Memorial Hospital Corporation | Parkersburg, WV | $5.25M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.